StreetInsider.com News Articles

Form EFFECT Xilio Therapeutics, Inc.

Mon, 01 Jun 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26578494.html

Form EFFECT Xilio Therapeutics, Inc.

Mon, 01 Jun 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26578494.html

Form S-3/A Xilio Therapeutics, Inc.

Wed, 27 May 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26559257.html

Form S-3/A Xilio Therapeutics, Inc.

Wed, 27 May 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260527/26559257.html

Form SCHEDULE 13G Xilio Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC

Fri, 15 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260515/26507071.html

Form SCHEDULE 13G Xilio Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC

Fri, 15 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260515/26507071.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Bain Capital Life Sciences Fund II, L.P.

Fri, 15 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26506613.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Bain Capital Life Sciences Fund II, L.P.

Fri, 15 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26506613.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26506388.html

Form SCHEDULE 13G/A Xilio Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26506388.html

Form SCHEDULE 13G Xilio Therapeutics, Inc. Filed by: Sirenia Capital Management LP

Fri, 15 May 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20260515/26499862.html

Form SCHEDULE 13G Xilio Therapeutics, Inc. Filed by: Sirenia Capital Management LP

Fri, 15 May 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20260515/26499862.html

Xilio Therapeutics (XLO) files $250M mixed shelf

Tue, 12 May 2026 07:57:02 -0400

Xilio Therapeutics (NASDAQ: XLO) has filed $250,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Units

Warrants

Xilio Therapeutics (XLO) files $250M mixed shelf

Tue, 12 May 2026 07:57:02 -0400

Xilio Therapeutics (NASDAQ: XLO) has filed $250,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Units

Warrants

Form S-3 Xilio Therapeutics, Inc.

Tue, 12 May 2026 07:49:00 -0400

si-local-file:///var/storage/secattach/20260512/26473145.html

Form S-3 Xilio Therapeutics, Inc.

Tue, 12 May 2026 07:49:00 -0400

si-local-file:///var/storage/secattach/20260512/26473145.html

Form 10-Q Xilio Therapeutics, Inc. For: Mar 31

Tue, 12 May 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260512/26473119.html

Form 10-Q Xilio Therapeutics, Inc. For: Mar 31

Tue, 12 May 2026 07:41:00 -0400

si-local-file:///var/storage/secattach/20260512/26473119.html

Form 8-K Xilio Therapeutics, Inc. For: May 12

Tue, 12 May 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260512/26473091.html

Form 8-K Xilio Therapeutics, Inc. For: May 12

Tue, 12 May 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260512/26473091.html

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Tue, 12 May 2026 07:30:00 -0400

On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting

Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1

Achieved development milestone under AbbVie collaboration and extended cash runway into early 2028

WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Tue, 12 May 2026 07:30:00 -0400

On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting

Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1

Achieved development milestone under AbbVie collaboration and extended cash runway into early 2028

WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Tue, 12 May 2026 07:30:00 -0400

On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting

Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1

Achieved development milestone under AbbVie collaboration and extended cash runway into early 2028

WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Tue, 12 May 2026 07:30:00 -0400

On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting

Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1

Achieved development milestone under AbbVie collaboration and extended cash runway into early 2028

WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Tue, 12 May 2026 07:30:00 -0400

On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2

Presented new preclinical data for XTX601, a potential first-in-class masked T cell engager targeting CLDN18.2, at the AACR annual meeting

Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1

Achieved development milestone under AbbVie collaboration and extended cash runway into early 2028

WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology